Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-Järvinen H, Fan JG, Grønbæk H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng MH, Fouad Y, Chan WK, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202–9.

Article  PubMed  Google Scholar 

Quek J, Ng CH, Tang ASP, Chew N, Chan M, Khoo CM, Wei CP, Chin YH, Tay P, Lim G, Tan DJH, Lim WH, Chan KE, Teng M, Tan E, Tamaki N, Huang DQ, Siddiqui MS, Young DY, Noureddin M, Muthiah MD. Metabolic associated fatty liver disease increases the risk of systemic complications and mortality. A meta-analysis and systematic review of 12 620 736 individuals. Endocr Pract. 2022;28(7):667–72.

Article  PubMed  Google Scholar 

Athyros VG, Katsiki N, Karagiannis A. Nonalcoholic fatty liver disease and severity of cardiovascular disease manifestations. Angiology. 2013;64(8):572–5.

Article  PubMed  Google Scholar 

European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Obes Facts. 2016;9(2):65–90.

Kaya E, Zedginidze A, Bechmann L, Canbay A. Metabolic dysfunction-associated fatty liver disease (MAFLD) and non-alcoholic fatty liver disease (NAFLD): distinct fatty liver entities with different clinical outcomes? Hepatobiliary Surg Nutr. 2022;11(2):299–301.

Article  PubMed  PubMed Central  Google Scholar 

Katsiki N, Gastaldelli A, Mikhailidis DP. Predictive models with the use of omics and supervised machine learning to diagnose non-alcoholic fatty liver disease: A “non-invasive alternative” to liver biopsy? Metabolism. 2019;101:154010.

Article  PubMed  Google Scholar 

Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne CD, Castro Narro GE, Chowdhury A, Cortez-Pinto H, Cryer DR, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Harrison SA, Kim SU, Koot BG, Korenjak M, Kowdley KV, Lacaille F, Loomba R, Mitchell-Thain R, Morgan TR, Powell EE, Roden M, Romero-Gómez M, Silva M, Singh SP, Sookoian SC, Spearman CW, Tiniakos D, Valenti L, Vos MB, Wong VW, Xanthakos S, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, Newsome PN. NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–86.

Article  PubMed  Google Scholar 

Kokkorakis M, Boutari C, Katsiki N, Mantzoros CS. From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need. Metabolism. 2023;147:155664.

Article  PubMed  Google Scholar 

European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;S0168–8278(24):00329–5.

Athyros VG, Tziomalos K, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J Gastroenterol. 2015;21(22):6820–34.

Article  PubMed  PubMed Central  Google Scholar 

Katsiki N, Athyros VG, Karagiannis A, Wierzbicki AS, Mikhailidis DP. Should we expand the concept of coronary heart disease equivalents? Curr Opin Cardiol. 2014;29(4):389–95.

Article  PubMed  Google Scholar 

Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism. 2016;65(8):1109–23.

Article  PubMed  Google Scholar 

Katsiki N, Perez-Martinez P, Anagnostis P, Mikhailidis DP, Karagiannis A. Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome? Curr Vasc Pharmacol. 2018;16(3):219–27.

Article  PubMed  Google Scholar 

Athyros VG, Alexandrides TK, Bilianou H, Cholongitas E, Doumas M, Ganotakis ES, Goudevenos J, Elisaf MS, Germanidis G, Giouleme O, Karagiannis A, Karvounis C, Katsiki N, Kotsis V, Kountouras J, Liberopoulos E, Pitsavos C, Polyzos S, Rallidis LS, Richter D, Tsapas AG, Tselepis AD, Tsioufis K, Tziomalos K, Tzotzas T, Vasiliadis TG, Vlachopoulos C, Mikhailidis DP, Mantzoros C. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement Metabolism. 2017;71:17–32.

Google Scholar 

Byrne CD, Targher G. Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications. Diabetes Obes Metab. 2022;24(Suppl 2):28–43.

Article  PubMed  Google Scholar 

Cazac GD, Lăcătușu CM, Mihai C, Grigorescu ED, Onofriescu A, Mihai BM. New Insights into Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: The Liver-Heart Axis. Life (Basel). 2022;12(8):1189.

PubMed  Google Scholar 

Ren Z, Simons PIHG, Wesselius A, Stehouwer CDA, Brouwers MCGJ. Relationship between NAFLD and coronary artery disease: A Mendelian randomization study. Hepatology. 2023;77(1):230–8.

Article  PubMed  Google Scholar 

Kasper P, Martin A, Lang S, Kütting F, Goeser T, Demir M, Steffen HM. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2021;110(7):921–37.

Article  PubMed  Google Scholar 

Matsubayashi Y, Fujihara K, Yamada-Harada M, Mitsuma Y, Sato T, Yaguchi Y, Osawa T, Yamamoto M, Kitazawa M, Yamada T, Kodama S, Sone H. Impact of metabolic syndrome and metabolic dysfunction-associated fatty liver disease on cardiovascular risk by the presence or absence of type 2 diabetes and according to sex. Cardiovasc Diabetol. 2022;21(1):90.

Article  PubMed  PubMed Central  Google Scholar 

Chen S, Xue H, Huang R, Chen K, Zhang H, Chen X. Associations of MAFLD and MAFLD subtypes with the risk of the incident myocardial infarction and stroke. Diabetes Metab. 2023;49(5):101468.

Article  PubMed  Google Scholar 

Vega L, Simian D, Gajardo AI, Salinas M, Urra A, Cattaneo M, Pino R, Roblero JP, Urzúa Á, Rojas K, Poniachik J. Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis. Ann Hepatol. 2024;29(4):101511.

Article  PubMed  Google Scholar 

Orzan RI, Gligor RI, Agoston R, Cionca C, Zlibut A, Pais R, Seicean A, Agoston-Coldea L. Metabolic Dysfunction Associated Liver Disease in Patients Undergoing Coronary Computed Tomography Angiography. J Cardiovasc Dev Dis. 2024;11(3):77.

PubMed  PubMed Central  Google Scholar 

Katsiki N, Mikhailidis DP, Wierzbicki AS. Epicardial fat and vascular risk: a narrative review. Curr Opin Cardiol. 2013;28(4):458–63.

Article  PubMed  Google Scholar 

Katsiki N, Athyros VG, Mikhailidis DP. Abnormal Peri-Organ or Intra-organ Fat (APIFat) Deposition: An Underestimated Predictor of Vascular Risk? Curr Vasc Pharmacol. 2016;14(5):432–41.

Article  PubMed  Google Scholar 

Katsiki N, Rizzo M, Mikhailidis DP. Epicardial, peripancreatic and other “orthotopic” excessive fat deposition in south Asians and Europeans: Are differences clinically relevant? J Diabetes Complications. 2023;37(4):108419.

Article  PubMed  Google Scholar 

Katsiki N, Mikhailidis DP. Perivascular Adipose Tissue: Pathophysiological Links With Inflammation, Atherosclerosis, and Thrombosis. Angiology. 2022;73(3):195–6.

Article  PubMed  Google Scholar 

Katsiki N, Dimitriadis G, Mikhailidis DP. Perirenal Adiposity and Other Excessive Intra- and Peri-Organ Fat Depots: What Is the Connection? Angiology. 2019;70(7):581–3.

Article  PubMed  Google Scholar 

Filippatos TD, Alexakis K, Mavrikaki V, Mikhailidis DP. Nonalcoholic fatty pancreas disease: Role in metabolic syndrome, “Prediabetes,.” Diabetes Atherosclerosis Dig Dis Sci. 2022;67(1):26–41.

Article  PubMed  Google Scholar 

Sanyal AJ, Husain M, Diab C, Mangla KK, Shoeb A, Lingvay I, Tapper EB. Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review. Am Heart J Plus. 2024;41:100386.

PubMed  PubMed Central  Google Scholar 

Zhang Z, Zheng M, Lei H, Jiang Z, Chen Y, He H, Zhao G, Huang H. A clinical study of the correlation between metabolic-associated fatty liver disease and coronary plaque pattern. Sci Rep. 2023;13(1):7224.

Article  PubMed  PubMed Central  Google Scholar 

De Filippo O, Di Pietro G, Nebiolo M, Ribaldone DG, Gatti M, Bruno F, Gallone G, Armandi A, Birtolo LI, Zullino V, Mennini G, Corradini SG, Mancone M, Bugianesi E, Iannaccone M, De Ferrari GM, D'Ascenzo F. Increased prevalence of high-risk coronary plaques in metabolic dysfunction associated stetatotic liver disease patients: A meta-analysis. Eur J Clin Invest. 2024;e14188. https://doi.org/10.1111/eci.14188

Lu C, Chen Y, Zhang Y, Zhao X. Liver Fibrosis Scores and Coronary Artery Disease: Novel Findings in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease. Diabetes Metab Syndr Obes. 2023;16:2627–37.

Article  PubMed  PubMed Central  Google Scholar 

Namakchian M, Rabizadeh S, Seifouri S, Asadigandomani H, Bafrani MA, Seifouri K, Avanaki FA, Rajab A, Nakhjavani M, Esteghamati A. Fibrosis score 4 index has an independent relationship with coronary artery diseases in patients with metabolic-associated fatty liver disease. Diabetol Metab Syndr. 2023;15(1):57.

Article  PubMed  PubMed Central  Google Scholar 

Wei Z, Huang Z, Song Z, Zhao W, Zhao D, Tan Y, Chen S, Yang P, Li Y, Wu S. Metabolic Dysfunction-associated fatty liver disease and incident heart failure risk: the Kailuan cohort study. Diabetol Metab Syndr. 2023;15(1):137.

Article